Les députés ont supprimé vendredi dernier la surtaxe d’Impôt sur les Sociétés proposée par le gouvernement français dans son PLF 2025. Il serait, selon nous, hasardeux de crier victoire trop tôt, et cette disposition pourrait faire son retour durant la suite du débat budgétaire, sous la forme initialement proposée par le gouvernement ou sous une autre. Nous restons prudents sur les actions françaises, le débat budgétaire restant chaotique et pas à la hauteur des enjeux, comme le souli...
Last Friday, MEPs scrapped the exceptional additional corporate tax proposed by the French government in its PLF 2025. In our view, it would be risky to claim victory prematurely, and this provision could make a comeback during the remainder of the budget debate, in the form initially proposed by the government or in another form. We remain cautious on French equities, as the budget debate remains chaotic and fails to live up to the stakes, as underlined by Moody's downgrade of the so...
>Q3 2024: growth in orders and revenues (organic) but contraction in the margin - Epiroc reported Q3 2024 results on the morning of Friday, 25 October that exceeded expectations in terms of orders and (organic) revenues, but a shade below for adjusted EBIT (3%). As was the case for Sandvik and Metso during the week, order intake was buoyant, with organic growth of 6% (consensus at 4.2%), including a 9% rise for E&S (11% for the equipment segment, with a record qu...
>T3 2024 : commandes et CA en croissance (organique) mais marge en recul - Epiroc a publié vendredi matin ses résultats T3 2024, qui étaient supérieurs aux attentes sur les commandes et le CA (organique), mais légèrement en dessous en ce qui concerne l'EBIT ajusté (3%). Comme pour Sandvik et Metso cette semaine, les prises de commandes étaient bien orientées avec une croissance organique de 6% (css à 4.2 %), dont une hausse de 9% pour E&S (11% pour la partie équi...
The Q3 report was in line overall, with orders and sales exactly in line with and adj. EBIT -1% versus consensus; however, the underlying margin again fell shy (50–60bp below in both divisions but only 20bp below consensus on group, as corporate costs were lower than expected). Epiroc guided for near-term demand to remain high in mining and remain weak in construction. We have made minor changes to our estimates and reiterate our HOLD, but have raised our target price to SEK215 (205).
>Q3 2024: strong orders (+6%) but margin still below consensus (19.7% vs 20%) - Epiroc reported this morning, its Q3 2024 results which slightly beat expectations on order intake but fell some way short on adjusted EBIT (3%).Order intake came in 6% higher in organic terms (consensus at 4.2%), underpinned by large orders (SEK 1,400m vs SEK 1,000m in Q3 2023) with E&S up 9% (including +11% for Equipment only) and T&A flat (supported by the demand for ground engagin...
>Q3 2024: strong orders (+6%) but margin still below consensus (19.7% vs 20%) - Epiroc reported this morning, its Q3 2024 results which slightly beat expectations on order intake but fell some way short on adjusted EBIT (3%).Order intake came in 6% higher in organic terms (consensus at 4.2%), underpinned by large orders (SEK 1,400m vs SEK 1,000m in Q3 2023) with E&S up 9% (including +11% for Equipment only) and T&A flat (supported by the demand for ground engagin...
>Still healthy commodities prices and demand that could accelerate if Chinese recovery materialises - In Q3, the trends remained broadly unchanged with demand stable at a high level in the mining sector, and limited demand in the construction sector (continuation – and end – of destocking by distributors and core demand still lacklustre in the short term, particularly in Europe). Detailed previews on page 2.The main commodities prices have held up relatively well...
>Des cours de matières premières toujours bien orientés et une demande qui pourrait accélérer si le rebond chinois se matérialise - Lors du T3, les tendances sont restées globalement inchangées avec une demande stable sur des niveaux élevés sur le secteur minier, et une faible demande sur le secteur de la construction (poursuite – et fin – du déstockage des distributeurs et demande sous-jacente toujours mal orientée à CT, notamment en Europe). Previews détaillés en pa...
We are removing GSK from our European Large Caps Convictions List. The company is the only one of the six Big Pharma groups to have experienced a break in trend, which could act as a drag on future publications. Our analyst adjusted this morning his EPS estimates for 2024/2025/2026 by -0.6%, 2.0% and- 3.4% respectively, factoring in weaker growth for Arexvy and Shingrix, hence the lowering of his target price from 2,150p to 1,900p. - ...
Nous sortons GSK de notre liste de valeurs recommandées Large Caps. La société est la seule des 6 big Pharma à connaître une rupture de tendance qui pourrait peser lors des prochaines publications. Notre analyste ajuste ce jour ses prévisions de BPA 24/25/26 de -0.6%/-2.0%/-3.4% intégrant une plus faible croissance pour Arexvy et Shingrix, ce qui conduit à une baisse de son objectif de cours de 2 150p à 1 900p. - ...
Accounting for an average of 19% of revenues for European capital goods groups (over 40% in some cases), the US is clearly a central factor in growth strategies, both organically and inorganically. Based on our analysis of the programmes of the two candidates running for the White House and the positioning of the various groups, we have established two scenarios through which to play the sector depending on the winner in November's election. In this still uncertain US election co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.